Most people comparing aesthetic treatments ask the same first question: how much does it cost? That is a fair question, but it is the second question that actually matters -- how much does it change your life?
The gap between those two questions is where a lot of money gets wasted and a lot of patients end up disappointed. A treatment can produce a measurable change on a clinical photo scale and still leave you feeling exactly the same about your face. Conversely, a less dramatic physical change can significantly shift your confidence, your social ease, and the way you move through your day. The field that tracks this rigorously is called health-related quality of life (HRQoL) research, and it is changing how thoughtful clinicians -- and regulators -- evaluate technologies from fillers to lasers to energy devices.
At NoMi Beach Health, Dr. Jezwah Harris (NP, JD, MBA, FNP-BC, MEP-C) built the aesthetics program around this principle: if we cannot point to evidence that a treatment improves how you actually feel, we are not offering it. Here is what that means in practice, and why it should change how you shop for aesthetic care.
Why "before and after" photos are not enough
Before-and-after photography is the dominant marketing format in aesthetic medicine, and it is also the least useful tool for predicting whether you will be satisfied with your results. A photo captures a single plane of light on a single day. It does not capture whether the person in that photo feels more comfortable in a meeting, less anxious before a date, or less likely to avoid mirrors.
Patient-reported outcome measures (PROMs) are standardized questionnaires designed to fill that gap. They ask patients directly -- before and after treatment -- how a condition or intervention affects their daily functioning, emotional wellbeing, and overall quality of life. They have been used in cardiology, oncology, and orthopedics for decades. Their application to aesthetic medicine is newer, but the literature is growing.
A 2025 review published in BJU International examined the challenges and opportunities of incorporating HRQoL data and PROMs into economic evaluations of medical technologies (https://pubmed.ncbi.nlm.nih.gov/42381123/). While the paper focused on urological technologies, its core argument applies cleanly to aesthetics: without patient-reported data, you are evaluating whether a technology works in the clinician's eyes, not in the patient's life. Health economists call this the difference between a clinical endpoint and a meaningful endpoint. The distinction matters enormously when you are spending real money.
In dermatology specifically, systematic reviews have found that PROMs capture dimensions of disease burden -- particularly social functioning and psychological impact -- that clinician assessments miss consistently (https://pubmed.ncbi.nlm.nih.gov/31733155/). If you have ever walked out of a treatment feeling like the clinician was satisfied even though you were not, this research explains why.
What the evidence actually says about popular aesthetic treatments
Let us be specific, because vague reassurance is not useful.
Dermal fillers have the longest track record in modern aesthetics and the widest evidence base. A 2025 review in the Journal of the German Dermatological Society summarized the current evidence on hyaluronic acid (HA) fillers: they are effective for volumization and contour correction, the anatomical principles governing safe injection are well-established, and the risk profile is manageable when the clinician understands facial vasculature and has emergency protocols in place (https://pubmed.ncbi.nlm.nih.gov/42329365/).
That last point is not a footnote. Vascular occlusion -- where filler material obstructs or compresses a blood vessel -- is rare but can cause tissue necrosis or, in the worst cases, vision loss. A 2025 paper in Dermatologic Surgery described protocols for ultrasound-guided hyaluronidase administration with remote expert guidance for exactly this emergency (https://pubmed.ncbi.nlm.nih.gov/42373049/). The clinical standard is clear: every provider offering HA fillers should have hyaluronidase available at every session and a documented protocol for vascular events. If you are considering filler and your provider cannot describe their emergency protocol, that is the information you needed.
Patient satisfaction data on well-placed filler is strong. A randomized prospective trial combining HA filler with botulinum toxin found high patient satisfaction scores on validated scales at follow-up, with durable results at 12 months (https://pubmed.ncbi.nlm.nih.gov/34862719/). The key phrase is "well-placed" -- anatomical knowledge and conservative volumes drive outcomes more than product brand.
Laser treatments for pigmentation are where the evidence base is growing fastest in 2025. Melasma -- patchy brown pigmentation driven by UV exposure, hormones, and genetic predisposition -- is one of the most common and most frustrating conditions we see. It is also one of the most studied in terms of laser technology.
A 2025 review in Dermatologic Clinics assessed the laser landscape for melasma and found that while multiple wavelengths show efficacy, recurrence remains a central challenge and the risk of post-inflammatory hyperpigmentation (PIH) is real, particularly in darker skin tones (https://pubmed.ncbi.nlm.nih.gov/42303356/). This is a tradeoff that matters enormously for our patient population in South Florida, where Fitzpatrick skin types III through VI are the norm rather than the exception.
A 2025 case series in Dermatologic Surgery reported on a combination protocol using microneedle radiofrequency followed by low-fluence 1064-nm picosecond Nd:YAG laser for melasma, finding meaningful improvement in Melasma Area and Severity Index (MASI) scores with an acceptable safety profile (https://pubmed.ncbi.nlm.nih.gov/42338292/). Separately, a pilot case series on Q-switched Nd:YAG laser for partial unilateral lentiginosis showed targeted clearance with manageable side effects (https://pubmed.ncbi.nlm.nih.gov/42349851/). These are small studies -- honest about that -- but they represent the direction the evidence is moving: combination protocols, lower fluence, and more attention to skin-type-specific outcomes.
How to think about cost when outcomes are what you are actually buying
This is where HRQoL research becomes practically useful for you as a consumer of aesthetic care.
A treatment that costs $800 and produces a result that lasts eight months and makes you noticeably more comfortable in your own skin has a very different value profile than a treatment that costs $400, produces a subtle result that fades in three months, and leaves you wondering whether you did anything at all. Standard economic analysis -- the kind used in health technology assessment -- calculates something called cost per quality-adjusted life year (QALY). Aesthetics does not have a robust QALY database yet, but the framework is useful: what are you paying, per unit of actual wellbeing gained?
A few honest principles follow from this:
Durability matters. A longer-lasting result at a higher upfront cost may be more economical than repeated low-cost treatments. Ask your provider how long results realistically last -- not the maximum case in ideal conditions, but the median outcome in patients like you.
Baseline matters. If you are treating active acne inflammation alongside pigmentation, a laser that ignores the inflammation may worsen it. Treating the right problem in the right order changes the cost-effectiveness calculation entirely. Our post on adult acne treatment covers how we sequence those decisions.
Skin tone matters in ways that most providers understate. Research confirms that racial and ethnic variations in skin physiology affect both the risk profile and the expected outcome of energy-based treatments (https://pubmed.ncbi.nlm.nih.gov/34236144/). A provider who does not adjust their approach based on your Fitzpatrick type is using evidence from a population that may not represent you.
Combination protocols may outperform single modalities -- but only when the evidence supports the combination, not because a provider wants to sell you two treatments instead of one. Every combination we offer at NBH has a peer-reviewed rationale behind it.
What a quality-of-life-centered aesthetic consultation looks like
When you come to NBH for an aesthetic consultation, Dr. Harris does not start by looking at your face and deciding what to fix. She starts by asking what bothers you, how much it bothers you in the context of your actual daily life, and what a successful outcome would look like for you -- not on a photo scale, but in the way you feel.
That framing changes what gets recommended. Someone who is self-conscious about filler-visible lips in a professional setting has different goals than someone who wants maximum volume for social photography. Someone whose melasma flares with every birth control pill change may need a hormonal conversation before a laser conversation. Someone on a GLP-1 medication like semaglutide (Wegovy) or tirzepatide (Zepbound) -- which we cover in depth in our GLP-1 outcomes guide -- may be experiencing facial volume loss that changes what aesthetic interventions make sense and in what order.
We also price transparently. You will know the cost of every treatment before anything touches your face, and we will tell you if we think a treatment is unlikely to produce the result you are hoping for. That conversation is part of what you are paying for at a concierge practice. We are not moving you through a protocol someone else designed for a different patient.
The bottom line on evidence, outcomes, and what you deserve to know
Aesthetic medicine is moving in the right direction -- toward standardized outcome measurement, honest risk disclosure, and patient-reported evidence rather than clinician-rated photo scores. The research is not complete, and we will tell you when the evidence on a specific protocol is limited. What it is not is absent. There is enough published, peer-reviewed data on fillers, lasers, and energy devices to make genuinely informed decisions -- if your provider knows where to look and is willing to be honest about what the data says.
You deserve a consultation where the evidence is quoted, the tradeoffs are named, and the recommendation is built around your quality of life, not a treatment menu.
If you are ready for that kind of conversation, explore our aesthetics services page or call us at (786) 744-5152 to book a new-patient consultation. We will look at what you want to change, what the evidence supports, and what a realistic plan looks like for your skin, your goals, and your budget -- and we will be honest about all three.
Frequently Asked Questions
- What is a patient-reported outcome measure (PROM) and why does it matter for aesthetic treatments?
- A PROM is a standardized questionnaire that captures how a treatment affects your daily life, confidence, and wellbeing -- directly from you, without a clinician interpreting it. In aesthetics, PROMs help separate treatments that improve how you look on paper from ones that actually improve how you feel day to day. Regulators and health economists increasingly require this data before recommending a technology.
- Is dermal filler worth the cost compared to laser treatments for pigmentation?
- It depends entirely on what you are treating. Filler restores volume and structure; lasers target pigment and texture. Head-to-head cost-effectiveness data comparing the two categories directly is limited, but quality-of-life research on both is growing. The honest answer is that the right choice is the one matched to your anatomy and your goals, not the one with the lowest sticker price.
- How do clinicians evaluate whether a laser treatment for melasma is evidence-based?
- We look for peer-reviewed data on efficacy, recurrence rates, and patient-reported satisfaction -- not just before-and-after photos. Technologies like picosecond Nd:YAG lasers and microneedle radiofrequency have published case series and small trials we can reference. We also weigh the risk of post-inflammatory hyperpigmentation, which is a real tradeoff in darker skin tones.
- What should I ask my provider before agreeing to a filler treatment?
- Ask what filler is being used and why, how vascular complications are managed (specifically whether hyaluronidase is on hand), what the expected duration of results is, and what the plan is if you are unhappy with the outcome. A clinician who cannot answer those questions clearly is a clinician you should leave.
- Are there risks with hyaluronic acid fillers that most patients do not know about?
- Vascular occlusion -- where filler is inadvertently injected into or compresses a blood vessel -- is rare but serious and can cause tissue loss or vision changes if not treated immediately. Published guidance now recommends that providers have hyaluronidase available at every filler session and know how to use it under ultrasound guidance when needed. This is one reason provider selection matters far more than product selection.
- How does NoMi Beach Health decide which aesthetic technologies to offer?
- We review the peer-reviewed evidence before adding any technology or injectable to our menu. If the data does not support a meaningful quality-of-life benefit -- not just a statistically significant change on a photo scale -- we do not offer it. We also price transparently so you can weigh cost against realistic outcomes before you commit.
- Can GLP-1 medications like semaglutide affect my aesthetic results?
- Yes -- significant weight loss from GLP-1 therapy can accelerate facial volume loss, which is sometimes called 'Ozempic face' in popular media. This is not a reason to avoid GLP-1s if you need them, but it is a reason to plan aesthetic treatments in coordination with your weight-loss protocol rather than in isolation. We discuss this at intake for any patient on both programs.
Sources
- Nguyen H, et al. Health-related quality of life and patient-reported outcome measures in economic evaluation of urological technologies: challenges and opportunities. BJU Int (2025).
- Jang H, et al. Ultrasound-Guided Hyaluronidase Administration with Remote Expert Guidance for Vascular Adverse Events after Filler Treatment. Dermatol Surg (2025).
- Hilton S, et al. Facial fillers: evidence base, anatomical principles, materials, risks, techniques, and future perspectives. J Dtsch Dermatol Ges (2025).
- Arora S, et al. Fading the spots: a pilot case series of partial unilateral lentiginosis treated with Q-switched Nd:YAG laser. J Cosmet Dermatol (2025).
- Shim JH, et al. Combination Therapy With Microneedle Radiofrequency Followed by Low-Fluence 1064-Nm Picosecond Neodymium-Doped Yttrium Aluminum Garnet Laser for Melasma: A Case Series. Dermatol Surg (2025).
- Trivedi MK, et al. Lasers for Melasma. Dermatol Clin (2025).
- Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992).
- Augustin M, et al. Patient-reported outcome measures in dermatology: a systematic review. J Eur Acad Dermatol Venereol (2020).
- Alexis AF, et al. Racial and ethnic variations in skin care concerns and practices. J Drugs Dermatol (2021).
- Philipp-Dormston WG, et al. A randomised, prospective, open-label clinical trial on patient satisfaction, aesthetic outcome, and safety of the combined use of a hyaluronic acid dermal filler and botulinum toxin in facial aesthetics. J Cosmet Dermatol (2022).
